The Lancet Oncology· Saby George, Ulka Vaishampayan, Alan Hutson, Adrienne Groman, Roberto Pili, Kelly Green, Laurie Herbst, Rushka Kallicharan-Smith, Ann-Marie DiRaddo, Elongia Farrell, Dharmesh Gopalakrishnan, Elisabeth Heath, Elizabeth Wulff, Deepak Kilari, Leonard Appleman, Rahul Parikh·· 4 小时前AI 评分32
帕唑帕尼（pazopanib）与贝伐珠单抗（bevacizumab）交替治疗既往未治疗的转移性透明细胞肾细胞癌：一项多中心、单臂I/II期临床试验
[Articles] Pazopanib alternating with bevacizumab in patients with metastatic clear-cell renal cell carcinoma naive to treatment: a multicentre, single-arm, phase 1/2 trial
AI 导读
帕唑帕尼（pazopanib）与贝伐珠单抗（bevacizumab）交替治疗在既往未治疗的转移性透明细胞肾细胞癌患者中显示出有前景的抗肿瘤活性。该多中心、单臂I/II期临床试验在I期确定了安全的II期推荐剂量；II期患者以预后良好风险组为主，结果仍需III期随机对照试验确认。
来源：The Lancet Oncology · thelancet.com